Sign In
Buy HRTX
$0.447
-0.0032 (-0.711%)
At Close: Jun 03, 2026
CINV Treatment Market Trends Report, 2020-2025
11:23am, Wednesday, 26'th Feb 2020
Dublin, Feb. 26, 2020 -- The "CINV Treatment Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering..
Biotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM Bio
12:00am, Wednesday, 26'th Feb 2020
So far Tuesday, February 25, NASDAQ is down -5.98% and the S&P is down -5.61%. Here are this morning’s most
Heron Therapeutics: Generic Competition And HTX-011 Approval May Put Pressure On Share Price
03:24pm, Tuesday, 25'th Feb 2020
Heron Therapeutics' 2 commercialised drugs for the treatment of acute and delayed nausea and vomiting associated with types of chemotherapy are under pressure f
American International Group Inc. Boosts Holdings in Heron Therapeutics Inc (NASDAQ:HRTX)
09:26am, Tuesday, 25'th Feb 2020
American International Group Inc. boosted its position in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 12.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exch
FY2021 EPS Estimates for Heron Therapeutics Inc (NASDAQ:HRTX) Lowered by Analyst
08:26am, Tuesday, 25'th Feb 2020
Heron Therapeutics Inc (NASDAQ:HRTX) – Stock analysts at Svb Leerink dropped their FY2021 earnings estimates for shares of Heron Therapeutics in a research report issued on Wednesday, February 19th.
Pacira price target raised to $63 from $60 at H.C. Wainwright PCRX;HRTX
12:11pm, Monday, 24'th Feb 2020
Pacira price target raised to $63 from $60 at H.C. Wainwright H.C. Wainwright PCRX HRTX
Heron Therapeutics (NASDAQ:HRTX) Shares Gap Down on Analyst Downgrade
06:44am, Saturday, 22'nd Feb 2020
Heron Therapeutics Inc (NASDAQ:HRTX)’s share price gapped down before the market opened on Thursday after Needham & Company LLC lowered their price target on the stock from $50.00 to $48.00. The sto
Heron Therapeutics (NASDAQ:HRTX) Rating Reiterated by Cantor Fitzgerald
06:22am, Saturday, 22'nd Feb 2020
Heron Therapeutics (NASDAQ:HRTX)‘s stock had its “buy” rating reiterated by research analysts at Cantor Fitzgerald in a report issued on Thursday, TipRanks reports. They currently have a $41.00
Heron Therapeutics: Looking For Entry Following HTX-011 PDUFA Extension
08:14pm, Friday, 21'st Feb 2020
Heron Therapeutics reported encouraging preliminary Q4/2019 results revealing CINVANTI continues to record impressive growth. The FDA extended Heron’s HTX-011 P
Ontario Teachers Pension Plan Board Buys Shares of 88,482 Heron Therapeutics Inc (NASDAQ:HRTX)
08:12pm, Friday, 21'st Feb 2020
Ontario Teachers Pension Plan Board bought a new stake in shares of Heron Therapeutics Inc (NASDAQ:HRTX) in the fourth quarter, according to the company in its most recent disclosure with the Securiti
Heron Therapeutics (HRTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
06:34pm, Friday, 21'st Feb 2020
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics Inc (NASDAQ:HRTX) Shares Purchased by Royce & Associates LP
05:47pm, Friday, 21'st Feb 2020
Royce & Associates LP increased its position in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 3.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securitie
Heron Therapeutics (HRTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
05:30pm, Friday, 21'st Feb 2020
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics Inc (NASDAQ:HRTX) Shares Bought by Great Lakes Advisors LLC
11:34am, Friday, 21'st Feb 2020
Great Lakes Advisors LLC grew its holdings in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 0.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 259,247 sha
